2023-506019-16-03Not yet recruitingPhase 1/2
CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III
Source: EU CTIS (euclinicaltrials.eu) · Last updated 31 Mar 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 82 (estimated)
- First submitted
- 25 Dec 2025
- Start date
- 30 Mar 2026
- Lead sponsor
- Celica d.o.o.
- Diseases
- Triple-negative breast cancer
- EU CT number
- 2023-506019-16-03
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 82
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Oncology Ljubljana | Ljubljana | Slovenia | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.